ArticleAIDS and behavior2026
Intravenous Methamphetamine Use, HIV Status and PrEP Uptake Among a U.S. Sample of 29,880 Gender and Sexual Minorities, 2022-2023.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interest in Long-Acting PrEP by Methamphetamine Use Among Men Who Have Sex with Men in Four Western US Cities.AIDS and behavior · 2026Article
- High Motivation but Low Access to PrEP: Social Determinants Undermine HIV Prevention Among Sexual and Gender Minority People Who Use Methamphetamine.AIDS and behavior · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Methamphetamine use is prevalent among sexual and gender minority (SGM) populations and is associated with increased risk for HIV acquisition. Studies are needed to examine the prevalence of intravenous methamphetamine use and explore its association with HIV status and PrEP uptake. Between August 2022-July 2023, 29,880 SGM people who have sex with men in the U.S. aged 16 and over completed a screening survey for a cohort study on methamphetamine use and HIV prevention. The survey captured socio-demographic characteristics, methamphetamine use (any and injection) and other substance use, and HIV-related measures (including current and previous PrEP use). The median age was 34 years and 49.7% were persons of color. Overall, 35.0% reported methamphetamine use; of whom 45.1% had injected it in the prior 12 months. Compared to people with non-injection methamphetamine use, respondents who injected methamphetamine were more likely to be older, white (vs. non-Hispanic Black or Hispanic), living with HIV or not know their status (vs. HIV-negative), to have injected cocaine, and to have had a sexual encounter without consent under the influence of alcohol/drugs. Among those who were HIV-negative, people who injected methamphetamine were less likely to currently take PrEP and more likely to have discontinued PrEP compared to those who reported non-injection methamphetamine use. Expanded efforts are needed to develop and implement targeted interventions, including PrEP and harm reduction approaches for SGM people who inject methamphetamine, to reduce risk of HIV and other infectious diseases, as well as other injection-related harms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.